PropertyValue
?:abstract
  • SARS-CoV-2, a novel pathogenic human coronavirus, emerged in December of 2019 in Wuhan (Hubei province, China) In most cases, the infection causes a mild to moderate respiratory illness However, a undefined group of infected may develop a severeor critical illness: Coronavirus disease 2019 (COVID-19) with acute respiratory distress syndrome (ARDS) and many other complications Current efforts are focused on limiting the spread of the virus in the population COVID-19 treatments are intensively evaluated, however, 8 months since the start of the pandemic and despite hundreds of clinical trials, our knowledge of effective treatments is still poor In this review, we present the current status of drugs and treatments used during SARS-CoV-2 infection Host-directed and virus-directed drugs, as well as new compounds specific for SARS-CoV-2 are presented
is ?:annotates of
?:creator
?:journal
  • Postepy_Mikrobiologii
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • COVID-19 therapy: What have we learned in 8 months?
?:type
?:who_covidence_id
  • #884146
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/sjhh6shw>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/sjhh6shw>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all